-
Eptinezumab, sold
under the
brand name Vyepti, is a
medication used for the
preventive treatment of
migraine in adults. It is a
monoclonal antibody that...
- SB-268262
Erenumab (AMG-334) is
approved for
prevention of migraine.
Eptinezumab (ALD403) is
approved for
prevention of migraine.
Fremanezumab (TEV-48125)...
-
Spreitzer H (3 July 2017). "Neue Wirkstoffe: Galcanezumab,
Fremanezumab und
Eptinezumab". Österreichische
Apothekerzeitung (in German) (14/2017). "Drug Approval...
-
menopausal depression,
insomnia and
resistant nausea/vomiting
Vyepti Eptinezumab Monoclonal antibody against CGRP
Migraine prevention Xe****ne, Nitoman...
- from the
original on 15 July 2020.
Retrieved 23
January 2020. "Vyepti-
eptinezumab-jjmr injection". DailyMed.
Archived from the
original on 28 September...
- N02CD02
Galcanezumab N02CD03
Fremanezumab N02CD04
Ubrogepant N02CD05
Eptinezumab N02CD06
Rimegepant N02CD07
Atogepant N02CX01
Pizotifen N02CX02 Clonidine...
-
medication manufactured by Allergan. Also FDA
approved in
February 2020,
eptinezumab (Vyepti), is an
intravenous migraine prophylactic medication manufactured...
- MK-3207
Olcegepant Rimegepant SB-268262
Telcagepant Ubrogepant Antibodies Eptinezumab Erenumab Fremanezumab Galcanezumab Agonists Cholecystokinin Antagonists...
- MK-3207
Olcegepant Rimegepant SB-268262
Telcagepant Ubrogepant Antibodies:
Eptinezumab Erenumab Fremanezumab Galcanezumab Agonists:
Cholecystokinin Antagonists:...
-
Medications in the anti-calcitonin gene-related peptide,
including eptinezumab, erenumab, fremanezumab, and galcanezumab,
appear to
decrease the frequency...
